How a muscle signal harms blood vessel repair in diabetes
MyomiR-499, Exosomes and Endothelial and Endothelial Progenitor Cells dysfunction in Diabetes
This project looks at whether a muscle-made tiny RNA (miR-499) carried in exosomes harms the cells that rebuild blood vessels in people with diabetes and leads to poor healing in badly reduced leg blood flow.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11307624 on NIH RePORTER |
What this research studies
Researchers will use diabetic mouse models and laboratory cell work to see if skeletal muscle releases exosomes carrying miR-499 that reach endothelial cells and endothelial progenitor cells and weaken their ability to grow new blood vessels. They will create limb ischemia in mice, measure blood flow and vessel repair, and change miR-499 levels in muscle or exosomes to observe effects on healing. The team will also study the molecular signaling steps inside blood-vessel cells that respond to miR-499. Together these approaches aim to show whether blocking or modifying this muscle-to-vessel signal could improve repair in diabetes.
Who could benefit from this research
Good fit: People with diabetes, particularly those with poor leg blood flow or early signs of critical limb ischemia, would be the most relevant group for future clinical testing based on these findings.
Not a fit: People without diabetes or whose limb problems come from non-vascular causes are unlikely to benefit directly from this research.
Why it matters
Potential benefit: If successful, the work could point to new ways to protect or restore blood-vessel repair and reduce the risk of critical limb ischemia in people with diabetes.
How similar studies have performed: Prior studies show that improving endothelial and endothelial progenitor cell function can help ischemic limb repair, but targeting muscle-derived miR-499 via exosomes is a newer approach with limited prior testing.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Kishore, Raj — Temple Univ of the Commonwealth
- Study coordinator: Kishore, Raj
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.